NEUROCRINE BIOSCIENCES INC (NBIX)
Neurocrine Biosciences Presents New Two-Year CRENESSITY® (crinecerfont) Data Demonstrating Durable Hormone Control, Reduced Glucocorticoid Exposure and Meaningful Clinical Improvements in Pediatric Patients with Classic Congenital Adrenal Hyperplasia
📈 **POSITIVE** • Medium confidence analysis (75%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business